Intensity Therapeutics, Inc. (INTS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Intensity Therapeutics reported revenue of $0. Net income was -$11.6M, or -$8.56 per diluted share. Operating activities generated -$9.2M of cash. At fiscal year end, Intensity Therapeutics held $14.1M in total assets against $2.2M in total liabilities, including $11.9M of cash and equivalents.
Open the full interactive Intensity Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Intensity Therapeutics Key Stats
| Share Price | $3.55 |
|---|---|
| Market Cap | $9.6M |
| 52-Week Range | $3.21 – $33.00 |
| Shares Outstanding | 2.7 million (basic, 2026 Q2) |
Intensity Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$8.3M | -$16.6M | -$12.0M |
| Pre-Tax Income | -$10.5M | -$16.3M | -$11.6M |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$10.5M | -$16.3M | -$11.6M |
| Diluted EPS | -$34.50 | -$29.25 | -$8.56 |
Intensity Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.7M | -$3.1M | -$2.4M | -$3.0M |
| Diluted EPS | -$1.50 | -$2.25 | -$0.96 | -$1.11 |
Intensity Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $8.6M | $2.6M | $11.9M |
| Current Assets | $15.5M | $3.4M | $12.7M |
| Total Assets | $17.3M | $4.8M | $14.1M |
| Current Liabilities | $4.0M | $1.8M | $2.1M |
| Total Liabilities | $4.1M | $1.9M | $2.2M |
| Shareholders' Equity | $13.2M | $2.9M | $11.9M |
Intensity Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$7.2M | -$15.2M | -$9.2M |
| Cash From Investing | -$6.0M | $6.4M | $0 |
| Cash From Financing | $20.5M | $2.9M | $18.6M |
Figures from Intensity Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Intensity Therapeutics financials page for every line item.
Intensity Therapeutics Company Profile
| Ticker | INTS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Shelton, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001567264 |
Frequently Asked Questions
What was Intensity Therapeutics' revenue in fiscal 2025?
Intensity Therapeutics (INTS) reported revenue of $0 for fiscal 2025.
What is Intensity Therapeutics' annual revenue history?
Intensity Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Intensity Therapeutics' net income in fiscal 2025?
Intensity Therapeutics reported net income of -$11.6M for fiscal 2025.
What was Intensity Therapeutics' earnings per share (EPS) in fiscal 2025?
Intensity Therapeutics' diluted EPS was -$8.56 for fiscal 2025 (adjusted for any later stock splits).
What was Intensity Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Intensity Therapeutics reported revenue of $0.
How many shares of Intensity Therapeutics are outstanding?
Intensity Therapeutics reported a weighted average of 2.7 million basic shares outstanding in 2026 Q2.
What is Intensity Therapeutics' market cap?
Based on its latest closing price, Intensity Therapeutics (INTS) has a market capitalization of about $9.6M.
When does Intensity Therapeutics' fiscal year end?
Intensity Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Intensity Therapeutics headquartered?
Intensity Therapeutics lists its business address in Shelton, Connecticut in its SEC filings.
Intensity Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →